CoChat

HER-2 and HER-3 expression in liver metastases of patients with colorectal cancer

Open access
Styczen, Hanna, Nagelmeier, Iris, Beissbarth, Tim, Nietert, Manuel, Homayounfar, Kia, Sprenger, Thilo, Boczek, Ute, Stanek, Kathrin, Kitz, Julia, Wolff, Hendrik A., Ghadimi, B. Michael, Middel, Peter, Liersch, Torsten, Rüschoff, Josef, Conradi, Lena-Christin · 2015 · Oncotarget
Cited by 29

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

// Hanna Styczen 1 , Iris Nagelmeier 2 , Tim Beissbarth 3 , Manuel Nietert 3 , Kia Homayounfar 1 , Thilo Sprenger 1 , Ute Boczek 1 , Kathrin Stanek 1 , Julia Kitz 4 , Hendrik A. Wolff 5 , B. Michael Ghadimi 1 , Peter Middel 2 , Torsten Liersch 1 , Josef Rüschoff 2 , Lena-Christin Conradi 1 1 Department of General, Visceral and Pediatric Surgery, University Medical Center, Göttingen, Germany 2 Targos Molecular Pathology, Pathology Nordhessen, Kassel, Germany 3 Department of Medical Statistics, University Medical Center, Göttingen, Germany 4 Department of Pathology, University Medical Center, Göttingen, Germany 5 Department of Radiotherapy and Radiooncology, University Medical Center, Göttingen, Germany Correspondence to: Lena-Christin Conradi, e-mail: lena.conradi@med.uni-goettingen.de Keywords: colorectal cancer, HER-2, HER-3, targeted therapy, liver metastases Received: January 25, 2015 Accepted: March 09, 2015 Published: April 13, 2015 ABSTRACT Objective: In this study, we evaluate the frequency of HER-2 and HER-3 expression in liver metastases from patients with colorectal cancer (CRLM). We analyzed the potential of HER-2 and HER-3 as therapeutic targets and evaluated their prognostic value. Patients and Methods: Overall 208 patients with CRLM were enrolled. HER-2 and HER-3 expression were determined in metastatic tissue of diagnostic punch biopsies ( n = 29) or resection specimens ( n = 179). The results of immunohistochemistry (IHC) scoring and In-situ-hybridization (ISH)-amplification were correlated with clinical parameters and for the 179 resected patients with cancer-specific (CSS) and overall survival (OS). The mean follow-up time was 56.7 months. Results: Positivity of HER-2 status (IHC score 2+/ISH+ and IHC 3+) was found in 8.2% of CRLM. High expression of HER-3 (IHC score 2+ and IHC 3+) was detected in 75.0% of liver metastases. CSS after liver surgery was determined and was independent from the HER-2 status ( p = 0.963); however HER-3 was prognostic with a favorable course for patients showing an overexpression of HER-3 ( p = 0.037). Conclusions: HER-2 overexpression occurs in only 8% of patients with CRLM but with 75% of cases HER-3 is frequently overexpressed in CRLM. Therefore, HER-2 and particularly HER-3 could serve as novel targets to be addressed within multimodal treatment approaches.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.3527

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 29

Metadata

Authors
Styczen, H., Nagelmeier, I., Beissbarth, T., Nietert, M., Homayounfar, K., Sprenger, T., Boczek, U., Stanek, K., Kitz, J., Wolff, H. A., Ghadimi, B. M., Middel, P., Liersch, T., Rüschoff, J., & Conradi, L.-C.
Venue
Oncotarget
Published
2015-04-13
Volume
6
Issue
17
Pages
15065-15076
ISSN
1949-2553 (ISSN-L)
OpenAlex
W1829134241
Cited by
29
References
6
FWCI
0.78
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.